Duchenne muscular dystrophy gene therapy: Lost in translation?
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
A milestone of molecular medicine is the identification of dystrophin gene mutation as the cause of Duchenne muscular dystrophy (DMD). Over the last 2 decades, major advances in dystrophin biology and gene delivery technology have created an opportunity to treat DMD with gene therapy. Remarkable success has been achieved in treating dystrophic mice. Several gene therapy strategies, including plasmid transfer, exon skipping, and adeno-associated virus-mediated microdystrophin therapy, have entered clinical trials. However, therapeutic benefit has not been realized in DMD patients. Bridging the gap between mice and humans is no doubt the most pressing issue facing DMD gene therapy now. In contrast to mice, dystrophin-deficient dogs are genetically and phenotypically similar to human patients. Preliminary gene therapy studies in the canine model may offer critical insights that cannot be obtained from murine studies. It is clear that the canine DMD model may represent an important link between mice and humans. Unfortunately, our current knowledge of dystrophic dogs is limited, and the full picture of disease progression remains to be clearly defined. We also lack rigorous outcome measures (such as in situ force measurement) to monitor therapeutic efficacy in dystrophic dogs. Undoubtedly, maintaining a dystrophic dog colony is technically demanding, and the cost of dog studies cannot be underestimated. A carefully coordinated effort from the entire DMD community is needed to make the best use of the precious dog resource. Successful DMD gene therapy may depend on valid translational studies in dystrophin-deficient dogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
X chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831
Utrophin–dystrophin-deficient mice as a model for Duchenne muscular dystrophy
Deconinck, A. E., Rafael, J. A., Skinner, J. A., Brown, S. C., Potter, A. C., Metzinger, L., Watt, D. J., Dickson, J. G., Tinsley, J. M., & Davies, K. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80532-2 · Cited by 752
MyoD is required for myogenic stem cell function in adult skeletal muscle
Megeney, L. A., Kablar, B., Garrett, K., Anderson, J. E., & Rudnicki, M. A. (1996) · Genes & Development · doi:10.1101/gad.10.10.1173 · Cited by 724
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 2×
“AAV vector.(113) This result was totally unpredicted by the mouse studies.”
BackgroundResultVery mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620 · cited 1×
“Whole-body delivery was first demonstrated with AAV serotype 6 in mdx mice by intravascular injection.(82)”
MethodInagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice
Wehling, M., Spencer, M. J., & Tidball, J. G. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200105110 · Cited by 530
Short Telomeres and Stem Cell Exhaustion Model Duchenne Muscular Dystrophy in mdx/mTR Mice
Sacco, A., Mourkioti, F., Tran, R., Choi, J., Llewellyn, M., Kraft, P., Shkreli, M., Delp, S., Pomerantz, J. H., Artandi, S. E., et al. (2010) · Cell · doi:10.1016/j.cell.2010.11.039 · Cited by 512
New recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs
Cooper, B. J., Winand, N. J., Stedman, H., Valentine, B. A., Hoffman, E. P., Kunkel, L. M., Scott, M.-O., Fischbeck, K. H., Kornegay, J. N., Avery, R. J., et al. (1988) · Nature · doi:10.1038/334154a0 · Cited by 428 · cited 1×
“The GRMD model is the best studied (Figure 2).(126,127) Beagle and GRMD models share the same mutation.”
MethodRecombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., & Byrne, B. J. (2006) · Circulation Research · doi:10.1161/01.res.0000237661.18885.f6 · Cited by 406
Characterization of Genome Integrity for Oversized Recombinant AAV Vector
Dong, B., Nakai, H., & Xiao, W. (2010) · Molecular Therapy · doi:10.1038/mt.2009.258 · Cited by 230
Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors
Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J. F., Chamberlain, J. S., & Duan, D. (2005) · Nature Biotechnology · doi:10.1038/nbt1153 · Cited by 224 · cited 1×
“expression has been achieved with all three dual-vector systems.(78,80,81) To address the third issue, investigators have”
BackgroundSelf-citationLiu, M., Yue, Y., Harper, S. Q., Grange, R. W., Chamberlain, J. S., & Duan, D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.013 · Cited by 178
Self-citationEfficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer
Lostal, W., Bartoli, M., Bourg, N., Roudaut, C., Bentaïb, A., Miyake, K., Guerchet, N., Fougerousse, F., McNeil, P., & Richard, I. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq065 · Cited by 173
Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb
Lai, Y., Yue, Y., & Duan, D. (2010) · Molecular Therapy · doi:10.1038/mt.2009.256 · Cited by 166
Self-citationGhosh, A., Yue, Y., Lai, Y., & Duan, D. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300322 · Cited by 161
Self-citationTailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155 · cited 1×
“The naturally occurring AAV serotypes and the molecularly engineered AAV capsids have offered essentially unlimited options for gene delivery.(61,62) The major drawback of AAV is its 5 kb packaging capacity.”
BackgroundGregorevic, P., Blankinship, M. J., Allen, J. M., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.28 · Cited by 120 · cited 1×
“a dystrophic mouse with AAV microdystrophin vectors.(91,92) The histopathology was ameliorated, muscle function improved, and life span prolonged.”
BackgroundGene Therapy of mdx Mice With Large Truncated Dystrophins Generated by Recombination Using rAAV6
Odom, G. L., Gregorevic, P., Allen, J. M., & Chamberlain, J. S. (2011) · Molecular Therapy · doi:10.1038/mt.2010.205 · Cited by 95 · cited 1×
“expression has been achieved with all three dual-vector systems.(78,80,81) To address the third issue, investigators have”
Background
Cited by
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy
McGreevy, J. W., Hakim, C. H., McIntosh, M. A., & Duan, D. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.018424 · Cited by 512
Self-citationZhang, Y., & Duan, D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.131 · Cited by 95
Self-citationFull-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors
Lostal, W., Kodippili, K., Yue, Y., & Duan, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.210 · Cited by 77
Self-citationZhang, Y., Yue, Y., Li, L., Hakim, C. H., Zhang, K., Thomas, G. D., & Duan, D. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt224 · Cited by 71
“Among dozens of abbreviated synthetic dystrophin constructs, the DH2-R19 minigene is the only one that we know works in human muscle (21).”
BackgroundSelf-citationPan, X., Yue, Y., Zhang, K., Lostal, W., Shin, J.-H., & Duan, D. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.044 · Cited by 30
Self-citation
Metadata
- Authors
- Duan, D.
- Venue
- Research and Reports in Biology
- Publisher
- Informa UK Limited
- Published
- 2011-03
- Volume
- 2011
- Issue
- 2
- Pages
- 31
- ISSN
- 1179-7274 (ISSN-L)
- OpenAlex
- W2126612843
- Cited by
- 56
- References
- 24
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.